Is Thymosin Alpha-1 Safe? Safety Profile 2026 — PeptidePrices

Q: Is Thymosin Alpha-1 safe?

Thymosin Alpha-1 has a safety rating of 8/10 in our methodology — good. 11,000+ patients in 30+ trials; well-tolerated; approved as Zadaxin globally; excellent safety record

Q: Is Thymosin Alpha-1 FDA approved?

FDA status: Approved in 30+ countries. PeptidePrices does not sell or recommend any compound for human use; this information is for research-context only.

Q: Where can I find verified Thymosin Alpha-1?

PeptidePrices tracks live prices and COA verification status across 30+ vendors. See our cheapest Thymosin Alpha-1 listings for prices ranked by COA tier and $/mg.

Safety Profile

Thymosin Alpha-1

Updated today

Cellular Peptide

8/10Good

How we score compound safety →

Primary use: Immune-modulation research

Regulatory Status

Approved in 30+ countries

Safety Summary

11,000+ patients in 30+ trials
well-tolerated
approved as Zadaxin globally
excellent safety record

Thymosin Alpha-1 sits in our well-studied tier (8/10). The safety dataset is robust, mechanisms are characterized, and side-effect patterns are predictable. Researchers working with this compound should still verify vendor COA quality — a clean safety profile means nothing if the vial contains the wrong compound or is under-dosed. Researchers often consider TB-500 and KPV as alternatives in the same category — see the related-compounds section below for safety comparisons.

Molecular Profile

TypeSynthetic acetylated polypeptide

Molecular Weight3,108.3 g/mol

Amino Acids28

CAS Number62304-98-7

SequenceAc-SDAAVDTSSEITTKDLKEKKEVVEEAEN

FormulaC₁₂₉H₂₁₅N₃₃O₅₅

Storage

Lyophilized2–8°C, stable long-term

Reconstituted2–8°C, within 30 days

Store refrigerated
Protect from light
Reconstitute with bacteriostatic water

Related Compounds

Methodology

How we rate peptide safety

Every compound in our index gets a 1–10 safety score based on four weighted factors. The score reflects known research-use risk — not medical advice.

40% — Clinical evidence. Volume of peer-reviewed trials, sample sizes, duration, and consistency of outcomes. FDA-approved compounds anchor the top end (8–10); preclinical-only compounds cap at 6.
30% — Adverse-event profile. Severity and frequency of reported side effects, including GI events, cardiovascular signals, hypoglycemia, and long-term organ effects.
20% — Regulatory status. FDA approval, EMA approval, or status in active clinical trials. Compounds under safety warnings are penalized.
10% — Community-reported outcomes. Reddit, forum, and published case-report signal beyond formal trials. Used as a late-stage tiebreaker, not a leading factor.

9–10Well-studied, FDA-approvedLarge-trial evidence, established long-term safety. Examples: semaglutide, tesamorelin at approved doses.

7–8Mostly safe, some caveatsPhase 2/3 evidence or long community track record with known manageable side effects. Routine monitoring recommended.

5–6Mixed dataLimited clinical trials, mostly community/preclinical data. Real but uncertain risk profile.

3–4Caution advisedKnown side-effect patterns, thin safety data, or compounds under active regulatory scrutiny.

1–2Significant risk signalsDocumented serious adverse events (cardiovascular, hepatotoxicity, contamination) or withdrawn regulatory status.

Related compounds

Other compounds researchers compare with Thymosin Alpha-1

Full Thymosin Alpha-1 profile Cheapest Thymosin Alpha-1 deals

Safety ratings are derived from published clinical data, FDA approval status, and community-reported outcomes. They are not medical advice. Always consult a healthcare professional before using any research compound.